PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
0.15%
Cash & equivalents yoy growth below half of AGEN's 248.81%. Michael Burry would question if the firm faces a liquidity squeeze. Check for rising debts or negative cash flow.
No Data
No Data available this quarter, please select a different quarter.
0.15%
Below half of AGEN's 255.61%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.11%
Below half of AGEN's 232.14%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-7.73%
Below half AGEN's 33.67%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-5.07%
Below half of AGEN's 29.96%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
0.03%
Below half of AGEN's 127.58%. Michael Burry sees a potential red flag for stagnation or capital shortage.
10.13%
Less than half of AGEN's 31.07%. David Dodd sees a more disciplined AP approach or lower volume.
-6.71%
Less than half of AGEN's -35.32%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-10.13%
Below half of AGEN's -30.09%. Michael Burry suspects a big gap in pre-sales traction.
6.71%
Less than half of AGEN's -19.60%. David Dodd sees fewer expansions in other current obligations.
8.18%
Less than half of AGEN's -11.04%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-95.12%
Above 1.5x AGEN's -9.79%. Michael Burry sees a strong spike vs. competitor. Check coverage and debt ratios.
No Data
No Data available this quarter, please select a different quarter.
6.04%
Less than half of AGEN's -10.26%. David Dodd sees far fewer liability expansions relative to competitor.
4.76%
Less than half of AGEN's 9.85%. David Dodd sees fewer share issuances vs. competitor.
-2.66%
Below half AGEN's 11.14%. Michael Burry suspects major net losses or high dividends vs. competitor.
100.00%
Less than half of AGEN's -31.92%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-0.27%
Below half AGEN's 116.94%. Michael Burry sees potential underperformance in building shareholder capital.
0.03%
Below half AGEN's 127.58%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-20.42%
Above 1.5x AGEN's -3.97%. Michael Burry sees a major jump. Investigate leverage rationale.
-0.28%
Less than half of AGEN's -1109.76%. David Dodd sees better deleveraging or stronger cash buildup than competitor.